Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2019 Nov;79(16):1819-1828. doi: 10.1007/s40265-019-01211-z.
Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.
乌帕替尼（Rinvoq™）是一种口服 Janus 激酶 1（JAK-1）抑制剂，由 AbbVie 公司研发，用于治疗类风湿关节炎。2019 年 8 月，基于在类风湿关节炎患者中开展的多国 III 期临床试验的积极结果，乌帕替尼在美国获得批准，用于治疗中重度活跃性类风湿关节炎和对甲氨蝶呤应答不足或不耐受的患者。本文总结了乌帕替尼研发过程中的重要里程碑，这些进展促成了该药在类风湿关节炎治疗领域的首次批准。
